ReviewMetabolites2020
Antifungal Drugs.
Review in Metabolites, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 121 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
121 citing papers in PubMed.
- Screening the γ-core Motif Peptides of Ascomycetous Antifungal Proteins for Antifungal Activity and Potential Therapeutic Applicability.Probiotics and antimicrobial proteins · 2026Article
- Potential Diagnostic and Research Applications of a Recombinant Antibody Directed Against Ferrated Triacetylfusarinine C fromJournal of fungi (Basel, Switzerland) · 2026Article
- Identification and characterization of a novel broad-spectrum antifungal compound targeting theMicrobiology spectrum · 2026Article
- A comprehensive review on antifungal compounds and biogenic nanoparticles from marine actinobacteria against opportunistic fungal infections.Folia microbiologica · 2026Review
- Metal-based triazoles as a medical marvel of the modern era: a comprehensive review.RSC advances · 2026Review
- Targeting Fructosamine Oxidase (Amadoriase II) inCurrent medicinal chemistry · 2026Article
- Article
- Discovery of a Caffeic Acid Thioamide with Potent Activity against Pathogenic Fungi and Fluconazole Tolerance-Eliminating Effects inDrug design, development and therapy · 2026Article
- Epidemiology of Fungal Bloodstream Infections and Antifungal Susceptibility in a Tertiary Care Hospital in Riyadh, Saudi Arabia: A RarePathogens (Basel, Switzerland) · 2025Article
- Ultrastructural and Immunohistochemical Study on the Nephrotoxicity Following Intravitreal Administration of the Antifungal Agents Voriconazole and Micafungin in New Zealand White Rabbits.International journal of molecular sciences · 2025Article
- Exploring fungal survival mechanisms: toward next-generation antifungal therapies against Candida spp.Archives of microbiology · 2025Review
- Article
- Chloroquine Alone and Combined with Antifungal Drug Against Candida albicans Biofilms In Vitro and In Vivo via Autophagy Inhibition.Mycopathologia · 2025Article
- Effects of novel organoantimony compounds on the fungal pathogenJournal of medical microbiology · 2025Article
- Antifungal Drugs for the Treatment of Invasive Fungal Infections-A Limited Therapeutic Toolbox Facing Growing Resistances.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Review
- Extracellular Vesicles From Fungal Infection in Humans: A Key Player in Immunological Responses.Journal of extracellular biology · 2025Article
- Mycobiome: an underexplored kingdom in cancer.Microbiology and molecular biology reviews : MMBR · 2025Review
- Aspergillosis: A comprehensive review of pathogenesis, drug resistance, and emerging therapeutics.Journal of food and drug analysis · 2025Review
- Importance of advancing antifungal treatments: a focus on chitinases and glucanases in Candida therapy.Archives of microbiology · 2025Review
61 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
We reviewed the licensed antifungal drugs and summarized their mechanisms of action, pharmacological profiles, and susceptibility to specific fungi. Approved antimycotics inhibit 1,3-β-d-glucan synthase, lanosterol 14-α-demethylase, protein, and deoxyribonucleic acid biosynthesis, or sequestrate ergosterol. Their most severe side effects are hepatotoxicity, nephrotoxicity, and myelotoxicity. Whereas triazoles exhibit the most significant drug-drug interactions, echinocandins exhibit almost none. The antifungal resistance may be developed across most pathogens and includes drug target overexpression, efflux pump activation, and amino acid substitution. The experimental antifungal drugs in clinical trials are also reviewed. Siderophores in the Trojan horse approach or the application of siderophore biosynthesis enzyme inhibitors represent the most promising emerging antifungal therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.